相关实验视频

Updated: Jan 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

通过脂质特异性转细胞形成诱导动脉硬性斑块回归的向性脂质转移纳米飞船

Shuling Tang^1,2,3,4, Yihao Cui^1,4, Yun Xiao^5,3

¹Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.

Advanced materials (Deerfield Beach, Fla.)

|October 16, 2025

概括

研究人员开发了LipShuttle,这是一个由脂质转移蛋白 (LTP) 启发的新型治疗平台,用于解决脂质过载疾病. 这种创新的方法准脂质滴并增强脂质的去除,显示了治疗动脉样硬化的前景.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
分子生物学分子生物学

背景情况:

脂质转移蛋白 (LTP) 对于膜间脂质转移至关重要,但面临治疗局限性.
现有的疗法难以平衡双膜向和脂质载体功能.

研究的目的:

开发一种新的治疗平台,LipShuttle,灵感来自LTPs,用于增强脂质去除.
调查LipShuttle在逆转脂质过载和治疗动脉样硬化的有效性.

主要方法:

设计的LipShuttle通过将β-cyclodextrin (β-CD) 与黄金纳米粒子合,用于向的脂质封存和排放.
在高脂肪饮食诱导的动脉样中的验证的LipShuttle在ApoE-/-小鼠中.
评估了斑块回归,炎症和巨细胞表型调节.

主要成果:

LipShuttle有效地准脂质滴,增强中性脂质代谢,并逆转泡细胞中的脂质过载.
超声波增强的LipShuttle疗法促进了动脉样硬化斑块的回归,并减少了小鼠的斑块脆弱性.
脂质枯竭抑制了阿拉基酸代谢,减少了炎症,并将巨细胞转移到亲细胞表型.

结论:

LipShuttle代表了一种有前途的基于脂质转移的治疗策略,用于因脂质积累失调而导致的疾病.
针对性和排放的双重机制为管理诸如动脉样硬化等复杂的脂质驱动病理提供了一种新的方法.

关键词:

动脉样硬化动脉样硬化生物材料是一种生物材料.泡细胞是一种泡细胞.纳米颗粒是一种纳米粒子.通过细胞转化 (transcytosis).

更多相关视频

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...